medigraphic.com
ISSN 1561-2937 (Print)

2021, Number 2

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2021; 27 (2)

Imaging multimodality in Cardiac amyloidosis: Case report and review

Padrón GKM, Peix GAT, Pérez BA, Hechavarría PS, Cabrera RLO, González VA, Gómez LJM

Language: Spanish
References: 37
Page:
PDF size: 746.50 Kb.


ABSTRACT

Amyloidosis is a systemic disease caused by amyloid proteins deposit in the tissues, producing functional and morphological disturbances. Many clinical types have been described, but only in two of them, cardiac damage has been found: light chain or transthyretin proteins deposits. They have different diagnosis, evolution, treatment and prognosis. The Red Congo endocardial biopsy is considered the gold standard for the positive diagnosis, while the type’s identification needs complex algorithms. Recently, the multimodality imaging approach in cardiac amyloidosis evaluation has been validated by experts’ consensus. In 2019 the multimodality imaging was introduced by our staff for cardiac amyloidosis assessment. We report the first case studied in our center and we review the current use of cardiac imaging in that entity.


REFERENCES

  1. Gertz MA. Amyloidosis. En: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016: Cap 188.

  2. Seldin DC, Berk JL. Amiloidosis. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Los-calzo J, eds. Harrison. Principios de Medicina Interna. 19ª ed. México, PA: McGraw-Hill; 2016:719-23. 3. Fusté Pedroso W, Emperador CR, González Gorrín M, Milán Castillo R, Luperón Loforte D, Castro Arca A, et al. Amiloidosis cardíaca. A propósito de un caso. CorSalud 2017;9(1):32-39.

  3. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195–201.

  4. Chao C, Pérez MD, Villegas A, Martínez J. Amiloidosis como causa de insuficiencia cardiaca. Rev Cub 2018; 57(2).

  5. Maurer MS, Bokhari S, Damy Thiabaud, Dorbala S, Drachman B, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail 2019; 12: e006075. doi: 10.1161/cirheartfailure.119.006075. Acceso sept 2019.

  6. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med 2017 Dec;84(12):12-26.

  7. Falk RH and Hershberger RE. The dilated, restrictive, and infiltrative cardiomyopathies. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Philadelphia, PA: Elsevier; 2019: cap 77.

  8. McKenna WJ, Elliott P. Diseases of the myocardium and endocardium. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016: cap 60.

  9. Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 2015; 20:163–78.

  10. Dorbala S, Ando Y, Bokahari S, Dispenzieri A, Falk R, Ferrari V, Fontana M. Consensus recommendations for multimodality imagines in cardiac amyloidosis. J Card Fail 2019; Part 1-2. doi.org/10.1016/j.cardfail.2019.08001. Acceso sept 2019.

  11. Dorbala S, Bokhari S, Miller E, Bullock-Palmer R, Soman P, Thompson R. Cardiac Amyloidosis ASNC practice points. J Nucl Cardiol 2016; 24: 234-45.

  12. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med 2018;28:10-21.

  13. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133(24):2404-12.

  14. Bokhari S, Morgenstern R, Weinberg R, Kinkhabwala M, Panagiotou D, Castano A, et al. Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. J Nucl Cardiol 2018; 25:181–90.

  15. White JA and Fine NM. Recent advances in cardiovascular imaging relevant to the management of patients with suspected cardiac amyloidosis. Curr Cardiol Rep 2016;18:77.

  16. Nativiti-Nicolau J, Maurer MS. Amiloidosis cardiomiopatía: puesta al día en el diagnóstico y tratamiento de los tipos más comunes. Curr Opin Cardiol 2018;33:571-9. doi:10.1097/HCO.0000000000000547. Acceso sept 2019.

  17. Agha AM, Parwani P, Guha A, Durand JB, Iliescu CA, Hassan S, et al. Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis. Open Heart 2018; 5: e000881. doi:10.1136/openhrt-2018-00088. Acceso sept 2020.

  18. González-López E, López-Sainz A, Garcia-Pavia P. Diagnóstico y tratamiento de la amiloidosis cardiaca por transtiretina. Progreso y esperanza. Rev Esp Cardiol 2017;70(11):991–1004.

  19. Phelan D, Collier P, Thavendiranathan P. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012; 98:1442e1448.

  20. Doherty JU, Kort S, Mehran R, Schoenhagen P, Soman P. ACC/ AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic, Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol 2019; 73:488–516.https://doi.org/10.1016/j.jacc.2018.10.038. Acceso nov 2019.

  21. Van der Meer P, Gaggin H, Dec W. ACC/AHA versus ESC Guidelines on Heart Failure JACC Guideline Comparison. J Am Coll Cardiol 2019; 73: 2756 – 68.https://doi.org/10.1016/j.jacc.2019.03.478. Acceso nov 2019.

  22. Chourabi C, Mahfoudhi H, Chenik S, Sayhi S, Dhahri R, Redissi A, et al. 2D Speckle tracking detects early left ventricular dysfunction in patients with cardiac sarcoidosis. Int J Clin Rheumatol 2020; 15: 188-92.

  23. Di Gesaro G, Tortorici E, Bellavia D, Licata P, Chiarello G, Liotta R, et al. Cardiac sarcoidosis: matching speckle-tracking echocardiography to macroscopic ventricular pathology. Int J Cardiol 2016; 203: 753-6.

  24. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, et al. CMR-based differentiation of AL and ATTR cardiac amyloid-dosis. JACC Cardiovasc Imaging 2014; 7: 133-42.

  25. Fontana M, Banypersad SM, Treibel TA,Maestrini V, Sado DM, White SK, et al. Native T1 mapping in transthyretin amyloidosis. J Am Coll Cardiol Img. 2014;7(2):157–65. https://doi.org/10.1016/j.jcmg.2013.10.008. Acceso oct 2020.

  26. Leiner T, Bogaert J, Friedrich M, Mohiaddin R, Muthurangu V, Myerson S, et al. SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2020; 22:76. https://doi.org/10.1186/s12968-020-00682-4. Acceso dic 2020.

  27. Bokhari S, Reehan S, Mathew MS. Radionuclide imaging in cardiac amyloidosis: Are nuclear bone tracers a foreseeable future? Curr Cardiovasc Imaging Rep 2015;8:1-7.

  28. AlJaroudi WA, Desai MY, Tang WHW, Phelan D, Cerqueira MD, Jaber WA. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: State of the art review and focus on emerging nuclear techniques. J Nucl Cardiol 2014;21:271-83.

  29. López-Fernández T, Saura D, Rodríguez-Palomares JF, Aguadé-Bruix S, Pérez de Isla L, Barba- Cosials J. Selección de temas de actualidad en imagen cardiaca 2015. Rev Esp Cardiol 2016;69: 286-93.

  30. Lee S, Lee ES, Choi H, Im H, Koh Y, Lee M, et al. 11 C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC: Cardiovasc Imaging 2014;8:50-9.

  31. Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR, Di Carli MF, et al. Imaging cardiac amyloidosis: A pilot study using 18Fflorbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014;41:1652-62.

  32. Scarlatelli Macedo A, Vellosa Schwartzmann P, Moreno de Gusmão B, Dantas Tavares de Melo M, Rizzi Coelho-Filho O. Advances in the treatment of Cardiac Amyloidosis. Curr Treat Options in Oncol 2020; 21: 36. DOI 10.1007/s11864-020-00738-8. Acceso dic 2020.

  33. Maurer M, Schwartz J, Gundapaneni B, Elliott P, Merlini G, Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018;379:1007-16. DOI: 10.1056/NEJMoa1805689. Acceso oct 2020.

  34. Bézard M, Kharoubi M, Galat A, Poullot E, Guendouz S, Fanen P, et al. Natural history and impact of treatment with tafamidis on major cardiovascular outcome free survival time in a cohort of patients with transthyretin amyloidosis. Eur J Cadiology 2020. https://doi.org/10.1002/ejhf.2028. (Abstract). Acceso dic 2020.

  35. Adams D, Gonzalez-Duarte A, O’RiordanWD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New Engl J Med 2018;379:11–21.

  36. Solomon SD, Adams D, Kristen A, Grogan M, González- Duarte A, Maurer MS, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin mediated amyloidosis: analysis of the APOLLO study. Circulation 2019;139:431–43.

  37. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018; 379:22–31.




2020     |     www.medigraphic.com